GIPR antagonist / GLP-1 agonist peptide-antibody
MariTide
Also known as AMG 133.
Stage Phase 2
Indications Obesity
Last updated:Jul 15, 2026Source:ClinicalTrials.gov + sponsor pipeline pagesVerified:Manually reviewedData provider:PeptidePlanet Research
Mechanism
Monthly-dosed peptide-antibody conjugate under evaluation for obesity.
Educational summary. Not medical advice. See sponsor materials and peer-reviewed literature for full pharmacology.
Companies developing it
1Related trials
1Current research
Data unavailableCurated peer-reviewed research links launch once our editorial pipeline is verified.
Safety summary
Data unavailableSafety summaries require a verified regulatory data source and clinical review. Consult the FDA label and sponsor prescribing information for approved products.